Invenomic Capital Management’s SS&C Technologies SSNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.88M Buy
+159,291
New +$10.8M 0.59% 61
2025
Q1
Sell
-369,861
Closed -$28M 199
2024
Q4
$28M Sell
369,861
-59,632
-14% -$4.46M 1.33% 16
2024
Q3
$31.9M Sell
429,493
-229,613
-35% -$16.3M 1.75% 11
2024
Q2
$41.3M Sell
659,106
-34,280
-5% -$2.13M 2.01% 9
2024
Q1
$44.6M Sell
693,386
-93,369
-12% -$5.8M 2.37% 4
2023
Q4
$48.1M Sell
786,755
-181,960
-19% -$9.94M 2.19% 5
2023
Q3
$50.9M Buy
968,715
+106,812
+12% +$6.11M 2.14% 8
2023
Q2
$52.2M Sell
861,903
-33,777
-4% -$1.92M 2.65% 6
2023
Q1
$50.6M Buy
895,680
+331,537
+59% +$19.1M 2.86% 3
2022
Q4
$29.4M Buy
564,143
+193,464
+52% +$9.81M 1.99% 11
2022
Q3
$17.7M Buy
+370,679
New +$21.3M 1.52% 18

Other funds holding SSNC

Invenomic Capital Management's SSNC Position: Q2 2026 in Review

Invenomic Capital Management opened a new position in SS&C Technologies (SSNC) in Q2 2026: 159,291 shares worth $9.88M. The stake represents 0.59% of the portfolio and ranks #61 among its holdings. This is a return to the name: Invenomic Capital Management previously reported a position in SSNC as recently as Q4 2024.

Invenomic Capital Management first reported a position in SSNC in Q3 2022 and has held it in 11 quarters since. The position peaked at $52.2M in Q2 2023. 722 funds tracked by Wall St. Rank hold SSNC as of Q2 2026.

  • Invenomic Capital Management held 159,291 shares of SS&C Technologies worth $9.88M as of Q2 2026.
  • SS&C Technologies was a new Invenomic Capital Management position in Q2 2026.
  • SS&C Technologies made up 0.59% of Invenomic Capital Management's portfolio in Q2 2026, its #61 holding.
  • Invenomic Capital Management first reported a position in SS&C Technologies in Q3 2022 and has held it in 11 quarters since.
  • Invenomic Capital Management's SS&C Technologies position peaked at $52.2M in Q2 2023.
  • 722 funds tracked by Wall St. Rank held SS&C Technologies as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.